Abstract 65P
Background
In healthy cells rather than being evenly distributed phosphatidylserine (PS) and phosphatidylethanolamine (PE) are found preferentially in the inner leaflet of the plasma membrane. Unlike normal cells, tumor cells lose the ability to maintain aminophospholipid asymmetry and expose PS naturally which promotes tumor growth and immune suppression by mechanisms that are not established. Since both PS and PE are co-regulated by the same transporters, in the case of PE translocation it might also serve as a specific lipid biomarker diagnostic the prognostic value of which is yet to be determined. We aimed to investigate whether hypoxia and low pH characteristics of tumor microenvironment (TME) might promote PE translocation on the surface leaflet of cancer cells membranes.
Methods
Ovarian cancer cells OVCAR-4 were incubated under standard (pH=7.5, O2=21%) and TME modeling conditions (pH=5.8, О2=1%) following with a two-step staining with PE-specific biotinylated Ro09 and streptavidin conjugated with Alexa Fluor 405. Propidium iodide (PI) staining was conducted to justify plasma membrane integrity. Visualization of PE on living OVCAR-4 cells was performed with the use of laser confocal microscopy.
Results
Under normoxic conditions a signal from PE was not detected on the surface of intact OVCAR-4 cells. However, under TME conditions cells were positive for PE staining, but not for PI, demonstrating that PE is translocated from the inner to the outer leaflet of cancer cell membrane.
Conclusions
Our results show that non apoptotic externalization of aminophospholipids in cancer cells has become a subject of great interest due to correlation with innate immune suppression and promotion of tumor growth. We propose that TME-driven surface exposure of PE, a second abundant phospholipid in cell membrane, coincides with constitutive PS externalization and can serve as a potential TME-specific therapeutic target and/or diagnostic tool for ovarian and other types of cancer.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Research Laboratory \"Biomarker\", Institute of Fundamental Medicine and Biology, Kazan Federal University.
Funding
This work has been supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis
Presenter: Eric Nakamura
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Identification of potential predictive biomarkers for ovarian cancer chemotherapy response
Presenter: Alsina Nurgalieva
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Rare RAS mutations are associated with recurrence patterns and recurrence-free survival in colon cancer: First results from Morocco
Presenter: Fatima Agy
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Development of a predictive model for response to neoadjuvant chemoradiation therapy of rectal cancer using the immunologic profile
Presenter: Eun Shin
Session: Cocktail & Poster Display session
Resources:
Abstract
152P - Biomarkers of neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
Presenter: Cibele Masotti
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - BRAF variants and therapy outcomes in melanoma
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - The impact of proton pump inhibitors in the prognosis of patients with non-metastatic nasopharyngeal carcinoma
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
155P - Use of machine learning for the identification of molecular biomarkers to predict response to neoadjuvant chemotherapy in locally advanced breast cancer patients
Presenter: María Del Río Pisula
Session: Cocktail & Poster Display session
Resources:
Abstract
156P - Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic
Presenter: Michal Eid
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - PCM4EU academy: An educational program for precision oncology
Presenter: Loic Verlingue
Session: Cocktail & Poster Display session
Resources:
Abstract